<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03102996</url>
  </required_header>
  <id_info>
    <org_study_id>Preserve-Transplant Study</org_study_id>
    <nct_id>NCT03102996</nct_id>
  </id_info>
  <brief_title>Preserve-Transplant Study</brief_title>
  <official_title>Preservation of Kidney Function in Kidney Transplant Recipients by Alkali Therapy (Preserve-Transplant Study): a Multi-center Randomized Single-blind Placebo- Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to test if alkali treatment will preserve kidney graft function and
      diminish the progression of chronic kidney disease in renal transplant patients. Additionally
      the underlying mechanisms of nephrotoxicity of metabolic acidosis will be investigated in
      this cohort.

      This study is a multi-center, prospective, randomized, single-blind (patient),
      placebo-controlled interventional trial to test the superiority of alkali treatment in
      comparison to placebo on preservation of kidney function in 300 kidney transplant recipients.
      The duration of the study will be 2 years for the individual participant. The patients will
      be randomized into 2 arms: intervention arm (sodium hydrogen carbonate, product:
      Nephrotrans®) and placebo arm (placebo comparator).

      Several studies in CKD (chronic kidney disease) patients have shown that alkali therapy slows
      progression of CKD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2017</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>eGFR</measure>
    <time_frame>2 years</time_frame>
    <description>Change in renal function by assessing the change in eGFR over 2 years from baseline. eGFR will be determined based on the CKD-EPI creatinine equation.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Acidosis</condition>
  <condition>Renal Insufficiency</condition>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Verum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive Nephrotrans.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive Placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nephrotrans</intervention_name>
    <description>Sodium hydrogen carbonate, ATC-Code: A02AH</description>
    <arm_group_label>Verum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Identical capsules without active substance.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent as documented by signature

          -  age ≥ 18 years and able to give informed consent

          -  ≥ 12 months after renal transplantation

          -  stable clinical condition

          -  stable graft function over the last 3 months (creatinine changes ± 15%)

          -  eGFR between 15-89 ml/min/1.73 m2

          -  serum bicarbonate ≤ 22 mmol/l within the last 6 months

        Exclusion Criteria:

          -  uncontrolled hypertension or use of &gt; 4 antihypertensive agents

          -  uncontrolled heart failure

          -  serum potassium &lt; 3.0 mmol/l

          -  serum sodium &gt; 150 mmol/l

          -  use of alkali in the preceding 4 weeks

          -  use of mineralocorticoid antagonists, topiramate, carbo anhydrase inhibitors or any
             drugs with similar effects

          -  history of noncompliance with clinic visits

          -  hereditary fructose intolerance

          -  known hypersensitivity or allergy to the drug used in this study or to peanut,
             sorbitol, and soy

          -  pregnancy or breastfeeding

          -  intention to become pregnant during the course of the study

          -  lack of safe contraception, defined as: Female participants of childbearing potential,
             not using and not willing to continue using a medically reliable method of
             contraception for the entire study duration, such as oral, injectable, or implantable
             contraceptives, or intrauterine contraceptive devices, or who are not using any other
             method considered sufficiently reliable by the investigator in individual cases.

          -  please note that female participants who are surgically sterilised / hysterectomised
             or post-menopausal for longer than 2 years are not considered as being of child
             bearing potential.

          -  suspected drug or alcohol abuse

          -  inability to follow the procedures of the study, e.g. due to language problems,
             psychological disorders, dementia, etc. of the participant

          -  enrolment of the investigator, his/her family members, employees and other dependent
             persons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nilufar Mohebbi, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rudolf P Wüthrich, Prof. Dr. med.</last_name>
    <role>Study Director</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nilufar Mohebbi, PD Dr. med.</last_name>
    <phone>0041442559589</phone>
    <email>nilufar.mohebbi@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Wiegand, MSc ETH</last_name>
    <email>anna.wiegand@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Inselspital Bern, Department of Nephrology and Hypertension</name>
      <address>
        <city>Bern</city>
        <state>BE</state>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Spyridon Arampatzis, PD Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HUG - Néphrologie</name>
      <address>
        <city>Geneva</city>
        <state>GE</state>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karine Hadaya, PD Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich, Division of Nephrology</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nilufar Mohebbi, PD Dr. med.</last_name>
    </contact>
    <contact_backup>
      <last_name>Anna Wiegand, MSc ETH</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2017</study_first_submitted>
  <study_first_submitted_qc>April 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2017</study_first_posted>
  <last_update_submitted>August 9, 2017</last_update_submitted>
  <last_update_submitted_qc>August 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alkali</keyword>
  <keyword>Graft</keyword>
  <keyword>Acid base</keyword>
  <keyword>Metabolic acidosis</keyword>
  <keyword>Chronic kidney disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Acidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

